Tivozanib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Regorafenib is a Small molecule drug targeting BRAF V600E x CRAF x CSF-1R x DDR2 x EphA2 x FGFR1 x FRK x MAPK11 x PDGFRα x PDGFRβ x RET x Tie-2 x TrkA x.

Avacopan is a Small molecule drug targeting C5AR1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Pegcetacoplan is a Synthetic peptide, Cyclic Peptide targeting C3, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Inebilizumab-cdon is a Monoclonal antibody targeting CD19, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Lunsekimig: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.

Zerlasiran is a siRNA targeting Lp(a), at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Masupirdine(Suven Life Sciences Ltd.): Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Sigvotatug vedotin: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Fosgonimeton: Suspended. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.

Trontinemab is a Bispecific antibody targeting APP x TfR1, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Zoldonrasib is a Non-degrading molecular glue targeting KRAS G12D, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.